ACXP - Acurx Pharmaceuticals, Inc.
IEX Last Trade
0.8165
-1.154 -141.274%
Share volume: 0
Last Updated: Tue 24 Dec 2024 02:30:01 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$1.97
-1.15
-58.55%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
6.06%
1 Month
-33.71%
3 Months
-53.21%
6 Months
-59.68%
1 Year
-77.03%
2 Year
-79.02%
Key data
Stock price
$0.82
DAY RANGE
$0.82 - $1.97
52 WEEK RANGE
$0.79 - $5.28
52 WEEK CHANGE
-$78.29
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: David P. Luci
Region: US
Website: www.acurxpharma.com
Employees: 3
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: www.acurxpharma.com
Employees: 3
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria.
Recent news